Inspire's Alleged Fraud NEW YORK--(BUSINESS WIRE)--Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G†) filed a class action in the U.S. District Court for the Southern District of New York alleging violations of the federal securities laws by Inspire Medical Systems, Inc. ("Inspire†or the "Company†) and certain of the Company's current senior executives (collectively, "Defendants†). The action is brought on behalf of all investors who purchased or otherwise ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 3845 (Primary Standard Industrial Classification Code Number) 30-0983531 (I.R.S. Employer Identification Number) 203 Redwood Shores Parkway, Suite 600 Redwood City, CA 94065 (904) 496-0027 (Address, including zip code, and telephone n ...

Core Insights - RxSight, Inc. announced the transition of Shelley Thunen from her role as Chief Financial Officer, effective until the appointment of her successor or January 31, 2026 [1] - Thunen will continue to support the company as a consultant after her transition [1] Group 1: Company Overview - RxSight, Inc. is focused on providing high-quality customized vision to patients following cataract surgery [3] - The company’s flagship product, the RxSight Light Adjustable Lens system, is the first and only commercially available intraocular lens technology that can be adjusted post-surgery [3] Group 2: Leadership Impact - Thunen has played a crucial role in RxSight's development, helping the company grow from a pre-commercial stage to having over 1,100 Light Delivery Devices (LDDs) in the field and performing over a quarter million procedures [2] - Her leadership was instrumental during significant milestones, including the company's initial public offering in 2021 [2]

Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) is highlighted as a top investment opportunity in the healthcare AI sector, with TD Cowen reaffirming a Buy rating and setting a price target of $115, naming it their "Best Idea for 2026" [1] Group 1: Growth Potential - TD Cowen describes Boston Scientific as "the most attractive growth story in the medical devices sector," supported by expectations of over 10% organic sales growth annually, 50 basis points of yearly operating margin expansion, and double-digit EPS growth [1][2] - Analysts anticipate that Boston Scientific will maintain double-digit organic revenue growth through 2026, despite facing tougher year-over-year comparisons [1] Group 2: Competitive Advantage - Boston Scientific's proven history of strong double-digit earnings growth justifies higher valuation multiples due to its "scarcity value," as few companies can match this reliable high growth [2] - Key products driving this growth include Farapulse for atrial fibrillation treatment and Watchman for stroke prevention [2] Group 3: Innovation and Market Strategy - At the 7th Annual Wolfe Research Healthcare Conference, Boston Scientific's management discussed the company's innovation pipeline and market expansion strategies, particularly in electrophysiology [3] - The Farapulse pulsed field ablation (PFA) system is projected to exceed 50% market penetration in the US by the end of 2025 [3] - Historical trials for the Watchman device were discussed, highlighting limitations from older device generations and post-procedure regimens [3] Group 4: Technological Integration - Boston Scientific develops medical devices across various fields, including cardiology, endoscopy, neuromodulation, and urology, utilizing machine learning, natural language processing, and computer vision to enhance medical imaging and patient management [4]

As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INSPIRA TECHNOLOGIES OXY B.H.N.LTD. (Exact name of registrant as specified in its charter) State of Israel 3841 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Nu ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of DexCom, Inc. about a class action lawsuit due to allegations of misleading statements and undisclosed material changes to their glucose monitoring products, which may have health implications for users [1][3]. Group 1: Allegations Against DexCom - The complaint alleges that DexCom made unauthorized design changes to its glucose monitoring products, the G6 and G7, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes reportedly rendered the G6 and G7 devices less reliable, posing a material health risk to users who depend on them for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability and accuracy, were allegedly overstated, and the company downplayed the severity of the issues related to the G7 devices [3]. Group 2: Legal and Financial Implications - The allegations suggest that DexCom is facing increased regulatory scrutiny and potential enforcement actions, which could lead to significant legal, reputational, and financial harm [3]. - The public statements made by DexCom were claimed to be materially false and misleading throughout the relevant period, which could impact investor confidence and stock performance [3]. Group 3: Class Action Participation - Shareholders who purchased shares of DXCM between January 8, 2024, and September 17, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff applications set for December 26, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to join [4].

Core Insights - Intuitive Surgical has seen a bearish sentiment from large investors, with 46% of trades being bearish compared to 38% bullish [1] - The price target for Intuitive Surgical is set between $400.0 and $700.0 based on recent options activity [2] - Analysts have set an average price target of $645.0 for Intuitive Surgical, with varying ratings from different firms [10][11] Options Trading Overview - A total of 26 options trades were detected, with 8 puts totaling $592,362 and 18 calls totaling $1,256,190 [1] - The volume and open interest metrics indicate significant investor interest in options with strike prices ranging from $400.0 to $700.0 over the past 30 days [3] - The largest observed options trades include a bullish call trade with a strike price of $680.0 and a bearish put trade with a strike price of $575.0 [7] Company Background - Intuitive Surgical specializes in developing and marketing robotic systems for minimally invasive surgery, with over 10,000 da Vinci systems installed globally [8] - The company has a strong presence in the U.S. with more than 6,000 installations and is expanding into emerging markets [8] Current Market Position - Intuitive Surgical's stock is currently trading at $576.0, reflecting a 0.62% increase, with a trading volume of 696,506 [13] - The anticipated earnings release is scheduled in 31 days, and RSI readings suggest the stock may be approaching overbought conditions [13]

Core Insights - Becton, Dickinson and Company (BDX) has announced a collaboration with the Institute for Immunology and Immune Health (I3H) to develop the BD FACSDiscover A8 Cell Analyzer, aimed at enhancing the understanding of the human immune system and supporting immune-mediated treatments [1][4] Collaboration Details - The partnership will conduct an immune profiling study involving 1,000 participants to analyze over 30 cellular functions in whole blood, focusing on how individual immune cells respond to drugs or diseases [1][9] - The study will utilize the BD FACSDiscover A8 Cell Analyzer and the BD Rhapsody System, along with BD's cell analysis instruments and software, to convert complex immune data into actionable insights [2][8] Market Performance - Following the announcement, BDX shares increased by 0.5%, with a 15.3% rise over the past six months, outperforming the industry growth of 4.9% and the S&P 500's increase of 16.3% [3] Strategic Implications - This collaboration reinforces BDX's commitment to advanced flow cytometry and immune profiling, enhancing its competitive position in the immunotherapy market by aligning with a leading academic institution [4][10] - The partnership aims to develop high-quality immune-based therapies, with the potential for peer-reviewed publications to validate BDX's technology and promote broader adoption in various research settings [9][10] Industry Outlook - The immunology market is projected to reach $108.40 billion by 2025, with a compound annual growth rate (CAGR) of 10.2% through 2034, driven by increasing healthcare spending and the prevalence of autoimmune disorders [11]

Core Viewpoint - Integer Holdings Corporation has faced significant challenges, leading to a reduction in its sales guidance for 2025 and a negative outlook for 2026, which has resulted in a substantial decline in its stock price [2][3]. Financial Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which is below prior expectations [2]. - The company anticipates net sales growth of –2% to 2% and organic sales growth of 0% to 4% for 2026 [2]. Product Performance - Management indicated that sales of three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower market adoption than forecasted [2]. - The Cardio & Vascular sales growth is expected to decelerate, primarily due to declines in the electrophysiology products, with this impact continuing into 2026 [2]. Stock Market Reaction - Following the announcement of the reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [3]. Legal Proceedings - A class action lawsuit has been filed alleging that Integer made materially false and misleading statements regarding its business and operations during the class period from July 25, 2024, to October 22, 2025 [4]. - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers [4].

Core Viewpoint - Medtronic plc is highlighted as a promising healthcare AI stock following the FDA's approval of its HUGO robotic-assisted surgery system, which is expected to enhance its competitive position in the surgical robotics market [1][2]. Group 1: FDA Approval and Market Impact - The FDA granted regulatory approval for Medtronic's HUGO robotic-assisted surgery system, marking the end of a lengthy development phase and enabling competition in the US surgical robotics market [2][3]. - The HUGO system is intended for minimally invasive urologic surgical procedures, including prostatectomy, nephrectomy, and cystectomy [3][4]. - Stifel anticipates that significant revenue contributions from the HUGO launch will not materialize until Medtronic's fiscal year 2027 [2]. Group 2: Clinical Study and Launch Strategy - The approval of the HUGO system followed positive outcomes from the Expand URO investigational device exemption clinical study, which is noted as the largest multi-center prospective IDE trial for multi-port robotic-assisted urologic surgery in the US [4]. - Medtronic plans a phased launch of the HUGO system, focusing on partnerships with leading hospitals to facilitate its introduction into the market [4]. Group 3: Company Overview - Medtronic plc develops and manufactures a range of medical devices and therapies across various sectors, including cardiovascular, diabetes, surgical, and neurological care [5]. - The company's AI-enabled product portfolio includes GI Genius, Touch Surgery Enterprise for surgical video analysis, AiBLE for neurosurgery, and the MiniMed 780G insulin pump [5].